14

tulos(ta)

Hakusana(t)
Julkaisutyyppi
Toimiala
Laatija
Hakusana
Päivämäärä

Stronger Bacteria. Weaker Antimicrobial, The fight against antimicrobial resistance in Europe through research, and the Andalusian PIRASOA program. Two examples of examples of success still to be completed

11-01-2018

The research is the key to the fight against Antimicrobial Resistance, but funding against the AMR in Europe is not acceptable because of the magnitude of the heath problem. In this context, in Andalusia (Spain), the PIRASOA Programme has been successfully implemented and developed, integrated into the daily clinical practice. The preliminary outcomes show a reduction of antimicrobial consumption and antimicrobial resistance and an improvement of antimicrobial prescription profile and. However, it ...

The research is the key to the fight against Antimicrobial Resistance, but funding against the AMR in Europe is not acceptable because of the magnitude of the heath problem. In this context, in Andalusia (Spain), the PIRASOA Programme has been successfully implemented and developed, integrated into the daily clinical practice. The preliminary outcomes show a reduction of antimicrobial consumption and antimicrobial resistance and an improvement of antimicrobial prescription profile and. However, it is necessary to maintain professional motivation and more technical and human resources.

Ulkopuolinen laatija

José Miguel Cisneros

Drugs package: Tackling new psychoactive substances

23-10-2017

Improving the EU's response to the rapid spread of new psychoactive substances has become urgent, and consequently Parliament is due to vote on a 'drugs package' during the October II plenary session. The package makes additions to the directive setting common minimum rules on criminal acts and penalties in the field of illicit drug trafficking, as well as corresponding amendments to the founding regulation of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).

Improving the EU's response to the rapid spread of new psychoactive substances has become urgent, and consequently Parliament is due to vote on a 'drugs package' during the October II plenary session. The package makes additions to the directive setting common minimum rules on criminal acts and penalties in the field of illicit drug trafficking, as well as corresponding amendments to the founding regulation of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).

Justice programme (2014-2020)

15-02-2017

The Justice programme aims at contributing to the development of the European area of justice based on mutual recognition of judicial decisions from the Member States and mutual trust between their national judiciaries. It promotes in particular judicial cooperation, judicial training, as well as effective access to justice in Europe, including rights of crime victims. The programme has been established by Regulation No 1382/2013 for the 2014-2020 period. All Member States except the United Kingdom ...

The Justice programme aims at contributing to the development of the European area of justice based on mutual recognition of judicial decisions from the Member States and mutual trust between their national judiciaries. It promotes in particular judicial cooperation, judicial training, as well as effective access to justice in Europe, including rights of crime victims. The programme has been established by Regulation No 1382/2013 for the 2014-2020 period. All Member States except the United Kingdom and Denmark participate.

A Review and Assessment of EU Drug Policy

28-11-2016

This study, commissioned by the European Parliament's Policy Department for Citizens' Rights and Constitutional Affairs at the request of the LIBE Committee, provides an overview of the drug policies in international fora, at EU level, in seven Member States and in three non-EU countries. The study highlights the very different approaches taken and their varying level of effectiveness.

This study, commissioned by the European Parliament's Policy Department for Citizens' Rights and Constitutional Affairs at the request of the LIBE Committee, provides an overview of the drug policies in international fora, at EU level, in seven Member States and in three non-EU countries. The study highlights the very different approaches taken and their varying level of effectiveness.

Ulkopuolinen laatija

Mirja GUTHEIL, Quentin LIGER, Aurelie HEETMAN, James EAGER and Solveig BOURGEON (Optimity Advisors)

Public expectations and EU policies - Health and social security

30-06-2016

Almost two thirds of EU citizens would like to see more EU engagement in the areas of health and social security. The EU's main role in these policies is to support and complement the activities of Member States, and it can encourage cooperation and best practice. EU health policy aims to foster good health, protect citizens from health threats and support dynamic health systems. Social policy promotes social cohesion equality as well as solidarity through adequate, accessible and financially sustainable ...

Almost two thirds of EU citizens would like to see more EU engagement in the areas of health and social security. The EU's main role in these policies is to support and complement the activities of Member States, and it can encourage cooperation and best practice. EU health policy aims to foster good health, protect citizens from health threats and support dynamic health systems. Social policy promotes social cohesion equality as well as solidarity through adequate, accessible and financially sustainable social protection systems and social inclusion policies. The EU encourages national pension reforms to ensure they are both adequate and sustainable. In the EU budget, the Health Programme 2014-2020 is the only programme specifically created for this policy area, but other programmes contribute in part to health objectives. EU spending on social security is tied to labour market measures.

The Paediatric Regulation: Are Children Still Missing Out on Potentially Life-Saving Treatments?

15-09-2015

This report summarises the presentations and discussions of the Workshop on "The Paediatric Regulation: Are children still missing out on potentially life-saving treatments?" held at the European Parliament in Brussels, on Tuesday 16 June 2015. The aim of the workshop was to discuss the main challenges and future perspectives related to the treatment of children in Europe in view of a potential future revision of the Paediatric Regulation. The first part of the workshop discussed the state of play ...

This report summarises the presentations and discussions of the Workshop on "The Paediatric Regulation: Are children still missing out on potentially life-saving treatments?" held at the European Parliament in Brussels, on Tuesday 16 June 2015. The aim of the workshop was to discuss the main challenges and future perspectives related to the treatment of children in Europe in view of a potential future revision of the Paediatric Regulation. The first part of the workshop discussed the state of play of the implementation of the Paediatric Regulation. The European Commission presented an overview of the findings of the 2013 Commission progress report on the Paediatric Regulation highlighting the remaining challenges. Some key problems, such as the difficulty to recruit quickly and to find a sufficient number of children patients to conduct clinical trials, were also presented from the industry perspective. The second part of the workshop focused on practical experiences and policy options for improved medicines for children. Still too often, children die from diseases which could be cured with the right treatments. All participants agreed that the Regulation provides a good basis, but that it needs further improvements and fine-tuning to ensure that children are not missing out on life-saving treatments. This workshop and the respective document were prepared by the Policy Department A at the request of the Committee on Environment, Public Health and Food Safety.

Ulkopuolinen laatija

Olga SOLOMON, Magda CHLEBUS, Karen and Mr Kevin CAPEL and Andrea BIONDI

Towards a Harmonised EU Assessment of the Added Therapeutic Value of Medicines

08-06-2015

TThis study, produced for the ENVI Committee by Policy Department A, investigates the possibility of a harmonised EU approach concerning the assessment of the added therapeutic value (ATV) of medicinal products. It reviews the current EU legal and policy framework and looks at the state-of-play within all 28 Member States. In addition, it presents the results of an in-depth analysis on the use of ATV in six selected EU countries. The study closes with policy recommendations on how a possible European ...

TThis study, produced for the ENVI Committee by Policy Department A, investigates the possibility of a harmonised EU approach concerning the assessment of the added therapeutic value (ATV) of medicinal products. It reviews the current EU legal and policy framework and looks at the state-of-play within all 28 Member States. In addition, it presents the results of an in-depth analysis on the use of ATV in six selected EU countries. The study closes with policy recommendations on how a possible European harmonisation of the ATV assessment might be taken forward within the current legal framework.

Ulkopuolinen laatija

VAN WILDER Philippe (Vrije Universiteit Brussel and SMART&BI), MABILIA Valentina (Milieu Ltd.), KUIPERS CAVACO Yoline (Milieu Ltd.) and MCGUINN Jennifer (Milieu Ltd.)

Proceedings of the Workshop on "Effectiveness of Medicines and Therapies"

12-12-2013

This report summarises the presentations and discussions at the Workshop on “Effectiveness of Medicines and Therapies”, held at the European Parliament in Brussels, on Wednesday 18 September 2013. The aim of the workshop was to exchange views on the latest developments and main challenges healthcare systems have to address while assessing risks and benefits of new drugs and therapies. The workshop was hosted by MEP Mr Alojz PETERLE (EPP, SL), Co-chair of the Health Working Group within the ENVI Committee ...

This report summarises the presentations and discussions at the Workshop on “Effectiveness of Medicines and Therapies”, held at the European Parliament in Brussels, on Wednesday 18 September 2013. The aim of the workshop was to exchange views on the latest developments and main challenges healthcare systems have to address while assessing risks and benefits of new drugs and therapies. The workshop was hosted by MEP Mr Alojz PETERLE (EPP, SL), Co-chair of the Health Working Group within the ENVI Committee.

Ulkopuolinen laatija

Tapani PIHA (DG SANCO, European Commission), Francesco PIGNATTI (Haematology and Diagnostics at European Medicines Agency - EMA), Jonathan CYLUS (European Observatory on Health Systems and Policies, London, the UK), Erik BAARS (University of Applied Sciences, Leiden, the Netherlands), Lidija GAJSKI (Croatian Association for Patients' Rights, Zagreb, Croatia)

Clinical trials: Initial Appraisal of the European Commission's Impact Assessment

15-02-2013

This note seeks to provide an initial analysis of the strengths and weaknesses of the European Commission's Impact Assessment on the Revision of the Clinical Trials Directive 2001/20/EC (SWD (2012) 200, SWD (2012) 201 (summary)) accompanying the Commission Proposal for a Regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (COM (2012) 369).

This note seeks to provide an initial analysis of the strengths and weaknesses of the European Commission's Impact Assessment on the Revision of the Clinical Trials Directive 2001/20/EC (SWD (2012) 200, SWD (2012) 201 (summary)) accompanying the Commission Proposal for a Regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (COM (2012) 369).

Proceedings of the Workshop "Advanced Therapy Medicinal Products"

15-02-2013

This report summarises the presentations and discussions at the Workshop on “Advanced Therapy Medicinal Products”, held at the European Parliament in Brussels, on Wednesday 20 February 2013. The aim of the workshop was to exchange views on the opportunities and challenges related to advanced therapies for the future of healthcare. The workshop was hosted by MEP Ms Glenis WILLMOTT (S&D, UK) and MEP Mr Alojz PETERLE (EPP, SL), Co-chairs of the Health Working Group within the ENVI Committee.

This report summarises the presentations and discussions at the Workshop on “Advanced Therapy Medicinal Products”, held at the European Parliament in Brussels, on Wednesday 20 February 2013. The aim of the workshop was to exchange views on the opportunities and challenges related to advanced therapies for the future of healthcare. The workshop was hosted by MEP Ms Glenis WILLMOTT (S&D, UK) and MEP Mr Alojz PETERLE (EPP, SL), Co-chairs of the Health Working Group within the ENVI Committee.

Ulkopuolinen laatija

Ms Sabine Jülicher, DG Health and Consumers, European Commission Prof. Stefaan Van Gool, Head of the Laboratory of Paediatric Immunology, University of Louvain (BE) Dr Jacques Mallet, Director of “Recherche Emérite” CNRS, Institute for Brain and Spinal Cord (ICM), Paris; Adjunct Professor at the University of California at San Francisco (UCSF); Member of the French Academy of Sciences (FR, US) Dr Monica Ensini, Scientific Director, European Organisation for Rare Diseases (EURORDIS) Dr Panos Kanavos, Reader in International Health Policy in the Department of Social Policy, London School of Economics (LSE) and Programme Director of the Medical Technology Research Group (MTRG) at LSE Health (UK) Dr Maria Luisa Nolli, Founder and Chief Executive Officer of Areta International (IT) Dr Christian K. Schneider, Chair, Committee for Advanced Therapies (CAT), European Medicine Agency

Tulevat tapahtumat

Kumppanit

Pysy ajan tasalla

email update imageSähköpostipäivitykset

Voit seurata ihmisiä ja asioita parlamentissa suoraan sähköpostiisi lähetettävien päivitysten avulla. Näin saat tuoreimmat uutiset muun muassa EP:n jäsenistä, valiokunnista, uutispalveluista ja Think Tank -osioista.

Järjestelmään pääsee miltä tahansa sivulta parlamentin verkkosivustolla. Se on helppo ottaa käyttöön: anna sähköpostiosoitteesi, valitse aihe, josta haluat saada ilmoituksia, ja ilmoita, kuinka usein haluat saada tietoa (päivittäin, viikoittain vai kuukausittain). Hetken kuluttua saat sähköpostin, jossa olevaa linkkiä napsauttamalla voit vahvistaa rekisteröitymisesi.

RSS imageRSS-syötteet

Voit seurata verkkosivustomme uutisia ja päivityksiä RSS-syötteiden avulla.

Napsauta alla olevaa linkkiä syötteiden konfiguroimiseksi.